Compare Summit Therapeutics Inc (SMMT) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Wolfspeed Inc — how do they compare? Summit Therapeutics Inc trades at $17.39 (market cap $13.71B), while Wolfspeed Inc trades at $31.55 (market cap $1.64B). The key difference: Summit Therapeutics Inc is far larger — about 8.4× Wolfspeed Inc's market cap, and Wolfspeed Inc is more actively traded (22,772,687 versus 6,173,057). Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Wolfspeed Inc for 19 Days on average.
| SMMT | WOLF | |
|---|---|---|
Market Cap | $13.71B | $1.64B |
Volume | 6,173,057 | 22,772,687 |
Sector | Health | Technology |
52-Week High | $26.38 | $73.68 |
52-Week Low | $12.43 | $14.80 |
Typical Hold Time | 16 Days | 19 Days |
Enterprise Value | $13.04B | $2.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% with strong technical momentum and bullish analyst sentiment. The stock shows negative profitability metrics but benefits from AstraZeneca's $2 billion strategic investment and clinical collaborations. Recent news highlights positive clinical trial results for ivonescimab, driving investor optimism despite current financial losses.
The outlook remains speculative with significant upside potential based on analyst consensus targets averaging $29.33, though high valuation multiples and negative cash flows present substantial risk. Success of clinical trials and partnership execution will determine long-term value creation for shareholders.
Wolfspeed (WOLF) trades at $31.37, down 1.45% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $1.61 billion in 2025, but forecasts a return to profitability in 2026 with a net income of $4 million. Recent news highlights the expansion of its 200mm silicon carbide portfolio, positioning it for growth in AI and electrification markets.
The outlook is mixed; analyst consensus is a buy with a $54.32 price target, but significant risks include negative margins, high debt, and ongoing legal investigations. Revenue growth in power devices offers upside, yet achieving breakeven remains critical for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
